Does Rallies show Form 4 insider transactions for AKBA?

Yes. Rallies tracks AKBA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AKBA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AKBA. It does not provide personalized investment advice.

AKBA (Akebia Therapeutics, Inc.) Stock Analysis - Insider Trades

Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of May 21, 2026, AKBA trades at $1.03 with a market cap of $270.94M and a P/E ratio of -12.30. AKBA moved +12.28% today. Year to date, AKBA is -33.11%; over the trailing twelve months it is -65.41%. Its 52-week range spans $0.88 to $4.08. Analyst consensus is strong buy with an average price target of $4.67. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AKBA stock inside the company?

Recent AKBA insider activity includes Butler John P. bought 69.27K, Malabre Richard C sold 36.14K, Malabre Richard C sold 13.38K, Grund Nicholas sold 53.59K, and Grund Nicholas sold 31.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AKBA Key Metrics

Key financial metrics for AKBA
Metric	Value
Price	$1.03
Market Cap	$270.94M
P/E Ratio	-12.30
EPS	$-0.08
Dividend Yield	0.00%
52-Week High	$4.08
52-Week Low	$0.88
Volume	26.35K
Avg Volume	0
Revenue (TTM)	$232.40M
Net Income	$-20.51M
Gross Margin	81.01%

Recent AKBA Insider Trades

Butler John P. bought 69.27K (~$86.59K) on Mar 4, 2026.
Malabre Richard C sold 36.14K (~$50.24K) on Feb 2, 2026.
Malabre Richard C sold 13.38K (~$18.60K) on Feb 2, 2026.
Grund Nicholas sold 53.59K (~$74.48K) on Feb 2, 2026.
Grund Nicholas sold 31.24K (~$43.43K) on Feb 2, 2026.

Latest AKBA News

Akebia Q1 Vafseo Sales Hit $15.8M with 60% Patient Growth, FSGS Trial Advances — May 7, 2026
Akebia Therapeutics Doses First Patients in 70-Participant Phase I AKB-9090 Trial — Apr 13, 2026
Akebia to Showcase Phase 2 FSGS, Basket Trials and Phase 1 AKB-9090 on April 2 — Mar 19, 2026
Akebia Reports 49% Revenue Jump to $227M, 290,000 Patients on Vafseo — Feb 26, 2026

AKBA Analyst Consensus

3 analysts cover AKBA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.67.

Common questions about AKBA

Who is trading AKBA stock inside the company?: Recent AKBA insider activity includes Butler John P. bought 69.27K, Malabre Richard C sold 36.14K, Malabre Richard C sold 13.38K, Grund Nicholas sold 53.59K, and Grund Nicholas sold 31.24K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AKBA?: Yes. Rallies tracks AKBA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AKBA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AKBA. It does not provide personalized investment advice.